Association of APOE epsilon4 and plasma p-tau181 with preclinical Alzheimer’s disease and longitudinal change in hippocampus function

Manuscript Number: 

21-0673R1

Author(s): 
Annelie Nordin Adolfsson, Rolf Adolfsson, Micael Andersson, Kaj Blennow, Anders Lundquist, Lars Nyberg, Alireza Salami, Michael Scholl, Henrik Zetterberg

Disclosures

Annelie Nordin Adolfsson

  • Nothing to Disclose

Rolf Adolfsson

  • Nothing to Disclose

Micael Andersson

  • Nothing to Disclose

Kaj Blennow

  • Patents/Royalties
    KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.

Anders Lundquist

  • Nothing to Disclose

Lars Nyberg

  • Nothing to Disclose

Alireza Salami

  • Nothing to Disclose

Michael Scholl

  • Nothing to Disclose

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave.
    Equity:
    HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.
    Lecture Fees:
    HZ has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche.